These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 21412130

  • 1. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL, Shih IeM.
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [Abstract] [Full Text] [Related]

  • 2. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
    Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IeM.
    Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
    [Abstract] [Full Text] [Related]

  • 3. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.
    N Engl J Med; 2010 Oct 14; 363(16):1532-43. PubMed ID: 20942669
    [Abstract] [Full Text] [Related]

  • 4. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma.
    Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL, Shih IeM.
    Am J Surg Pathol; 2013 Sep 14; 37(9):1342-8. PubMed ID: 24076775
    [Abstract] [Full Text] [Related]

  • 5. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IeM.
    Int J Gynecol Cancer; 2012 Oct 14; 22(8):1310-5. PubMed ID: 22976498
    [Abstract] [Full Text] [Related]

  • 6. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
    BMC Cancer; 2014 Feb 22; 14():120. PubMed ID: 24559118
    [Abstract] [Full Text] [Related]

  • 7. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
    Khalique S, Naidoo K, Attygalle AD, Kriplani D, Daley F, Lowe A, Campbell J, Jones T, Hubank M, Fenwick K, Matthews N, Rust AG, Lord CJ, Banerjee S, Natrajan R.
    J Pathol Clin Res; 2018 Jul 22; 4(3):154-166. PubMed ID: 29659191
    [Abstract] [Full Text] [Related]

  • 8. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2012 Apr 22; 25(4):615-24. PubMed ID: 22157930
    [Abstract] [Full Text] [Related]

  • 9. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF, McIntyre JB, Taylor J, Lee S, Ogilvie T, Sienko A, Morris D, Duggan MA, McCluggage WG, Köbel M.
    Am J Surg Pathol; 2017 May 22; 41(5):685-695. PubMed ID: 28125452
    [Abstract] [Full Text] [Related]

  • 10. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M, Schmoeckel E, Hertlein L, Rottmann M, Jeschke U, Mayr D.
    PLoS One; 2018 May 22; 13(2):e0192881. PubMed ID: 29451900
    [Abstract] [Full Text] [Related]

  • 11. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L, Bussaglia E, Rodrguez I, Gallardo A, Pons C, Irving JA, Prat J.
    Hum Pathol; 2004 Nov 22; 35(11):1360-8. PubMed ID: 15668893
    [Abstract] [Full Text] [Related]

  • 12. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
    Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen LA, Trovik J, Salvesen HB.
    Mod Pathol; 2013 Mar 22; 26(3):428-34. PubMed ID: 23080032
    [Abstract] [Full Text] [Related]

  • 13. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
    Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A.
    Int J Gynecol Cancer; 2012 Jan 22; 22(1):9-14. PubMed ID: 22193641
    [Abstract] [Full Text] [Related]

  • 14. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
    Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IeM.
    J Natl Cancer Inst; 2014 Jul 22; 106(7):. PubMed ID: 24899687
    [Abstract] [Full Text] [Related]

  • 15. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN, McConechy MK, Köbel M, Han G, Rouzbahman M, Davidson B, Irving J, Ali RH, Leung S, McAlpine JN, Oliva E, Nucci MR, Soslow RA, Huntsman DG, Gilks CB, Lee CH.
    Am J Surg Pathol; 2013 Sep 22; 37(9):1421-32. PubMed ID: 24076778
    [Abstract] [Full Text] [Related]

  • 16. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
    Allo G, Bernardini MQ, Wu RC, Shih IeM, Kalloger S, Pollett A, Gilks CB, Clarke BA.
    Mod Pathol; 2014 Feb 22; 27(2):255-61. PubMed ID: 23887303
    [Abstract] [Full Text] [Related]

  • 17. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I, De Leo A, D'Angelo E, Rosa-Rosa JM, Corominas M, Gonzalez A, Palacios J, Prat J.
    Hum Pathol; 2018 Feb 22; 72():100-106. PubMed ID: 29133142
    [Abstract] [Full Text] [Related]

  • 18. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A, Kuhn E, Wu RC, Ogawa H, Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM, Wang TL.
    Mod Pathol; 2017 Feb 22; 30(2):297-303. PubMed ID: 27767100
    [Abstract] [Full Text] [Related]

  • 19. Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.
    Coatham M, Li X, Karnezis AN, Hoang LN, Tessier-Cloutier B, Meng B, Soslow RA, Blake Gilks C, Huntsman DG, Stewart CJ, Postovit LM, Köbel M, Lee CH.
    Mod Pathol; 2016 Dec 22; 29(12):1586-1593. PubMed ID: 27562491
    [Abstract] [Full Text] [Related]

  • 20. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM.
    J Pathol; 2010 Feb 22; 220(3):392-400. PubMed ID: 19967725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.